Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-hMG
- Development stage
- Unknown
- Lead developer
- Granata Bio
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
GB-hMG is a proprietary investigational human menopausal gonadotropin (hMG) being developed by Granata Bio Corporation for the treatment of infertility in women undergoing assisted reproductive technology (ART). As a biologic gonadotropin hormone preparation, it contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. These hormones target gonadotropin receptors on ovarian cells to stimulate follicular development and ovulation. The drug is currently being evaluated in the pivotal Phase 3 GRACE study (Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth with Frozen Transfer), which assesses its efficacy and safety for ovarian stimulation and cumulative live birth in women undergoing IVF. Granata Bio has entered into a royalty purchase agreement with Gedeon Richter for this hMG program.
- Other names
- human menopausal gonadotropinhMG
02
Targets
FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on GB-hMG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-hMG.